QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

NCT00074698 ·Status: COMPLETED ·Phase: PHASE1

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

NCT02510937 ·Status: COMPLETED ·Phase: PHASE1

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

NCT07283770 ·Status: RECRUITING ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

NCT02532764 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

NCT01216046 ·Status: COMPLETED ·Phase: PHASE1

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.

NCT00308243 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

NCT03375047 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT02649751 ·Status: TERMINATED ·Phase: PHASE2

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752 ·Status: WITHDRAWN ·Phase: PHASE3

28 Day Repeat Dose in Cystic Fibrosis Patients

NCT00903201 ·Status: COMPLETED ·Phase: PHASE2

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

NCT04126473 ·Status: COMPLETED ·Phase: PHASE2

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

NCT05076149 ·Status: COMPLETED ·Phase: PHASE3

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

NCT02759562 ·Status: TERMINATED ·Phase: PHASE2

NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients

NCT00809094 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

NCT00467831 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis

NCT00757848 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF

NCT03748199 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

NCT00056147 ·Status: COMPLETED ·Phase: PHASE2

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

NCT00865904 ·Status: COMPLETED ·Phase: PHASE2

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527 ·Status: COMPLETED ·Phase: PHASE1

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080 ·Status: COMPLETED ·Phase: PHASE3

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

NCT00503490 ·Status: COMPLETED ·Phase: PHASE1